Business
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance
NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue
About this update from Mdxhealth Sa
[{"type":"text","content":"NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The Company expects to report 2022 revenues of approximately $37 million, with a year-end cash balance of $15.5 million. The Company is also reaffirming its previously issued 2023 revenue guidance of $65-$70 million. Michael K. McGarrity, CEO of mdxhealth, commented: “In 2023, we are focused on operating execution and believe that improved reimbursement, along with our expanded diagnostic product offering will drive growth as reflected in our guidance. With the recent acquisition from Exact Sciences of the Genomic Prostate Score® (GPS) test (formerly Oncotype DX GPS), we believe mdxhealth is now a leader in the field of personalized diagnostic solutions focused exclusively on urology, and that our expanded menu will provide our urology customers with a more comprehensive offering of clinically actionable diagnostics to support a clear pathway for patients suspected of or diagnosed with prostate cancer. We are committed to building value for all of our stakeholders including patients, customers and shareholders.” About mdxhealth® Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at:twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth. 2023 Reporting Calendar March 1, 2023: 2022 FY resultsApril 26, 2023: Q1-2023 business updateMay 25, 2023: Annual general shareholders’ meetingAugust 23, 2023: Publi...